{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:20:55Z","timestamp":1783948855641,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jocn.2022.05.002","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:11:25Z","timestamp":1652314285000},"page":"89-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Comparison of neutrophil-to-lymphocyte ratio between myelin oligodendrocyte glycoprotein antibody-associated disease and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders in adults"],"prefix":"10.1016","volume":"101","author":[{"given":"Zhenghao","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jocn.2022.05.002_b0005","doi-asserted-by":"crossref","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J Neuroinflammation"},{"issue":"3","key":"10.1016\/j.jocn.2022.05.002_b0010","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/WCO.0000000000000446","article-title":"Myelin oligodendrocyte glycoprotein antibodies: How clinically useful are they?","volume":"30","author":"Reindl","year":"2017","journal-title":"Curr Opin Neurol"},{"issue":"9","key":"10.1016\/j.jocn.2022.05.002_b0015","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/dmcn.13703","article-title":"Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes","volume":"60","author":"Duignan","year":"2018","journal-title":"Dev Med Child Neurol"},{"issue":"21","key":"10.1016\/j.jocn.2022.05.002_b0020","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGDOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jocn.2022.05.002_b0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00415-017-8651-4","article-title":"Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai","volume":"265","author":"Zhao","year":"2018","journal-title":"China J Neurol"},{"issue":"2","key":"10.1016\/j.jocn.2022.05.002_b0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.jocn.2022.05.002_b0035","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.intimp.2016.04.006","article-title":"Neutrophil to lymphocyte ratio(NLR) and platelet to lymphocyte ratio (PLR) were associated with disease activity in in patients with systemic lupus erythematosus","volume":"36","author":"Wu","year":"2016","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"10.1016\/j.jocn.2022.05.002_b0040","first-page":"141","article-title":"Neutrophil-to-Lymphocyte Ratio (NLR) in Canine Inflammatory Bowel Disease (IBD)","volume":"7","author":"Benvenuti","year":"2020","journal-title":"Vet Sci"},{"key":"10.1016\/j.jocn.2022.05.002_b0045","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2147\/NDT.S311942","article-title":"Neutrophil-to-lymphocyte ratio on admission is an independent risk factor for the severity of neurological impairment at disease onset in patients with a first episode of neuromyelitis optica spectrum disorder","volume":"Volume 17","author":"Zhou","year":"2021","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"10.1016\/j.jocn.2022.05.002_b0050","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12883-019-1245-2","article-title":"The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis","volume":"19","author":"Hemond","year":"2019","journal-title":"BMC Neurol"},{"issue":"1","key":"10.1016\/j.jocn.2022.05.002_b0055","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/WCO.0000000000000766","article-title":"Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis","volume":"33","author":"Chen","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.jocn.2022.05.002_b0060","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, Flanagan EP, et al. Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders. 2018, 75(11):1355-1363.","DOI":"10.1001\/jamaneurol.2018.1814"},{"issue":"2","key":"10.1016\/j.jocn.2022.05.002_b0065","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2022.05.002_b0070","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3389\/fimmu.2017.01785","article-title":"Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Opitca[J]","volume":"8","author":"Wang","year":"2017","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jocn.2022.05.002_b0075","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/cells8030285","article-title":"IL-6, IL-12 and IL-23 STAT-pathway genetic risk and responsiveness of lymphocytes in patients with myltiple sclerosis","volume":"8","author":"von Essen","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.jocn.2022.05.002_b0080","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.msard.2018.12.002","article-title":"Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models","volume":"27","author":"Wu","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jocn.2022.05.002_b0085","doi-asserted-by":"crossref","unstructured":"Takeshita Y, Obermeier B, Cotleur AC, Spampinato SF, Shimizu F, et al. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm 2016; 4(1): e311.","DOI":"10.1212\/NXI.0000000000000311"},{"issue":"14","key":"10.1016\/j.jocn.2022.05.002_b0090","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.7150\/ijms.61153","article-title":"The role and mechanisms of Microglia in Neuromyelitis Optica Spectrum Disorders","volume":"18","author":"Li","year":"2021","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.jocn.2022.05.002_b0095","doi-asserted-by":"crossref","unstructured":"Sayed A, Bahbah EI, Kamel S, Barreto GE, Ashraf GM, Elfil M. The neutrophil-to-lymphocyte ratio in Alzheimer\u2019s disease: current understanding and potential applications. J Neuroimmunol 2020; 349: 577398.","DOI":"10.1016\/j.jneuroim.2020.577398"},{"issue":"7","key":"10.1016\/j.jocn.2022.05.002_b0100","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.4049\/jimmunol.1301296","article-title":"Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases","volume":"191","author":"Mayer","year":"2013","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.jocn.2022.05.002_b0105","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"H\u00f6ftberger","year":"2020","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.jocn.2022.05.002_b0110","doi-asserted-by":"crossref","unstructured":"Kwon YN, Kim B, Ahn S, Seo J, Kim SB, Yoon SS, et al. Serum level of IL-1\u03b2 in patients with inflammatory demyelinating disease: Marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD). J Neuroimmunol 2020; 348: 577361.","DOI":"10.1016\/j.jneuroim.2020.577361"},{"key":"10.1016\/j.jocn.2022.05.002_b0115","doi-asserted-by":"crossref","unstructured":"Elsbernd PM, Hoffman WR, Carter JL, Wingerchuk DM. Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review. Mult Scler Relat Disord 2021; 48: 102696.","DOI":"10.1016\/j.msard.2020.102696"},{"key":"10.1016\/j.jocn.2022.05.002_b0120","doi-asserted-by":"crossref","unstructured":"Shimizu F, Ogawa R, Mizukami Y, Watanabe K, Hara K, Kadono C, et al. GRP78 antibodies are associated with blood-brain barrier breakdown in anti\u2013Myelin oligodendrocyte glycoprotein antibody-associated disorder. Neurol Neuroimmunol Neuroinflamm 2021; 9(1): e1038.","DOI":"10.1212\/NXI.0000000000001038"},{"issue":"2","key":"10.1016\/j.jocn.2022.05.002_b0125","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1152\/physrev.00012.2018","article-title":"The Neutrophil's Role During Health and Disease","volume":"99","author":"Liew","year":"2019","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jocn.2022.05.002_b0130","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.msard.2018.07.025","article-title":"MOG antibody disease: A review of MOG antibody seropositive neuromuelitis optica spectrum disorder","volume":"25","author":"Narayan","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.jocn.2022.05.002_b0135","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10.1016\/j.jocn.2022.05.002_b0140","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s10072-017-3068-5","article-title":"Neutrophil to lymphocyte ratio may be a helpful marker to evaluate disease activity in NMOSD","volume":"38","author":"Lin","year":"2017","journal-title":"Neurol Sci"},{"key":"10.1016\/j.jocn.2022.05.002_b0145","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s12883-021-02432-0","article-title":"Association of neutrophil-to-lymphocyte ratio (NLR) with the prognosis of first attack neuromyelitis optica spectrum diorder (NMOSD): a retrospective cohort study","volume":"21","author":"Xie","year":"2021","journal-title":"BMC Neurol"},{"issue":"3","key":"10.1016\/j.jocn.2022.05.002_b0150","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/ene.12898","article-title":"Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands","volume":"23","author":"Pelt","year":"2016","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jocn.2022.05.002_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102345","article-title":"Neurtrophil-to-lymphocyte ratio was correlated with disease activity in myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD) in children","volume":"45","author":"Benetou","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jocn.2022.05.002_b0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.628024","article-title":"An abnormally high neutrophil-to-lymphocyte ratio is not an independent outcome predictor in AQP4-IgG-Positive NMOSD","volume":"12","author":"Carnero Contentti","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jocn.2022.05.002_b0165","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00415-020-10322-7","article-title":"Neutrophil-to-lymphocyte ratio: a marker of neuro-inflammation in multiple sclerosis?","volume":"268","author":"Gelibter","year":"2021","journal-title":"J Neurol"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586822002168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586822002168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:31:00Z","timestamp":1760823060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586822002168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":33,"alternative-id":["S0967586822002168"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2022.05.002","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of neutrophil-to-lymphocyte ratio between myelin oligodendrocyte glycoprotein antibody-associated disease and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders in adults","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2022.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}